|
|
||||||||
J Thorac Cardiovasc Surg 2005;130:1310
© 2005 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
Read at the C. Walton Lillehei Resident Competition at the Eighty-fifth Annual Meeting of The American Association for Thoracic Surgery, San Francisco, Calif, April 10-13, 2005.
Received for publication April 7, 2005; revisions received June 30, 2005; accepted for publication July 19, 2005. * Address for reprints: Ren-Ke Li, MD, PhD, NU 1-115, 200 Elizabeth Street, Toronto General Hospital, Toronto, Ontario, Canada M5G-2C4 (Email: renkeli{at}uhnres.utoronto.ca).
OBJECTIVE: We hypothesized that implantation of adult mesenchymal stem cells after acute myocardial infarction mobilizes bone marrow precursor cells by activating the stem cell factor pathway, and that overdriving this pathway would enhance the beneficial effects of cell transplantation.
METHODS: After coronary ligation, medium, mesenchymal stem cells, or stem cell factoroverproducing mesenchymal stem cells were injected into the anterior left ventricle. Cells from ß-galactosidase transgenic mice enabled tracking of injected cells. The global and local impact of the cells was evaluated by measuring cytokine levels, endothelial progenitor cells, and myocardial angiogenesis, and by addressing cardiomyogenesis with confocal microscopy. The impact on cardiac function was evaluated by pressure-volume loops. Ventricular morphometrics were measured after in situ perfusion-fixation of the hearts at physiologic pressures.
RESULTS: Implantation of mesenchymal stem cells increased myocardial stem cell factor levels 2.0-fold, endothelial progenitor cell mobilization 2.7-fold, and myocardial angiogenesis 2.3-fold (P < .05), but did not induce mitogenesis in host cardiomyocytes or give rise to ß-galactosidaseexpressing cardiomyocytes. Cell-transplanted groups had improved indices of cardiac function, including preload recruitable stroke work and end-systolic elastance (P < .001). Cell transplantation resulted in 2.0-fold smaller ventricular volumes (P = .001) and 2.0-fold reduced infarct scar area (P = .056), but had no effect on the volume of spared myocardium. Stem cell factor overproduction imparted greater functional benefit without inducing detectable histologic cardiomyocyte regeneration.
CONCLUSION: Mesenchymal stem cell implantation after myocardial infarction facilitates functional cardiac regeneration without myocyte regeneration through augmentation of endogenous infarct repair, which is enhanced by stem cell factor.
This article has been cited by other articles:
![]() |
H. Reinecke, E. Minami, W.-Z. Zhu, and M. A. Laflamme Cardiogenic Differentiation and Transdifferentiation of Progenitor Cells Circ. Res., November 7, 2008; 103(10): 1058 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Fazel, D. Angoulvant, J. Butany, R. D. Weisel, and R.-K. Li Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1388 - 1389. [Full Text] [PDF] |
||||
![]() |
P. Farahmand, T. Y.Y. Lai, R. D. Weisel, S. Fazel, T. Yau, P. Menasche, and R.-K. Li Skeletal Myoblasts Preserve Remote Matrix Architecture and Global Function When Implanted Early or Late After Coronary Ligation Into Infarcted or Remote Myocardium Circulation, September 30, 2008; 118(14_suppl_1): S130 - S137. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. da Silva Meirelles, A. I. Caplan, and N. B. Nardi In Search of the In Vivo Identity of Mesenchymal Stem Cells Stem Cells, September 1, 2008; 26(9): 2287 - 2299. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-D. Kan, S.-H. Li, R. D. Weisel, S. Zhang, and R.-K. Li Recipient Age Determines the Cardiac Functional Improvement Achieved by Skeletal Myoblast Transplantation J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1086 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cimini, S. Fazel, S. Zhuo, M. Xaymardan, H. Fujii, R. D. Weisel, and R.-K. Li c-Kit Dysfunction Impairs Myocardial Healing After Infarction Circulation, September 11, 2007; 116(11_suppl): I-77 - I-82. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vincentelli, F. Wautot, F. Juthier, O. Fouquet, D. Corseaux, S. Marechaux, T. Le Tourneau, O. Fabre, S. Susen, E. Van Belle, et al. In vivo autologous recellularization of a tissue-engineered heart valve: Are bone marrow mesenchymal stem cells the best candidates? J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 424 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Thibault, L. Gomez, E. Donal, G. Pontier, M. Scherrer-Crosbie, M. Ovize, and G. Derumeaux Acute myocardial infarction in mice: assessment of transmurality by strain rate imaging Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H496 - H502. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hernando Insua, A. D. Montaner, J. M. Rodriguez, F. Elias, J. Flo, R. A. Lopez, J. Zorzopulos, E. L. Hofer, and N. A. Chasseing IMT504, the Prototype of the Immunostimulatory Oligonucleotides of the PyNTTTTGT Class, Increases the Number of Progenitors of Mesenchymal Stem Cells Both In Vitro and In Vivo: Potential Use in Tissue Repair Therapy Stem Cells, April 1, 2007; 25(4): 1047 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, T. Yasuda, R. D. Weisel, and R.-K. Li Enhanced cell transplantation: preventing apoptosis increases cell survival and ventricular function Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H939 - H947. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |